Defendant Name:
DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation)
Defendant Type:
Public Company
SIC Code:
2834
CUSIP:
00547W30
Document Reference:
33-11353
Document Details
Legal Case Name
In the Matter of DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation) and Robert O. Hopkins
Document Name
Order Instituting Administrative and Cease-and-Desist Proceedings, Pursuant to Section 8A of the Securities Act of 1933, Sections 4C and 21C of the Securities Exchange Act of 1934, and Rule 102(e) of the Commission's Rules of Practice, Making Findings, and Imposing Remedial Sanctions and a Cease-and-Desist Order
Document Date
14-Jan-2025
Document Format
Administrative Proceeding
Allegation Type
Issuer Reporting and Disclosure
Document Summary
On January 14, 2025, the SEC instituted settled administrative and cease-and-desist proceedings against DMK Pharmaceuticals Corporation, formerly known as Adamis Pharmaceuticals Corporation, and Robert O. Hopkins, stating: "These proceedings arise out of an accounting and disclosure fraud case concerning DMK Pharmaceuticals Corporation f/k/a Adamis Pharmaceuticals Corporation (“DMK Pharmaceuticals” or “Adamis”) and Robert O. Hopkins, its former Chief Financial Officer."
Disgorgement & Penalty Information
Resolutions
Cease and Desist Order
Cooperation Before the Resolution
Remedial Acts or Efforts Before the Resolution
Monetary Penalties:
Disgorgement
Individual:
$313,613.00
Shared:
Pre-Judgment Interest
Individual:
$20,701.00
Shared:
Total Penalty
Individual:
$334,314.00
Shared:
Other Defendants in Action:
